{"id":42300,"date":"2023-05-30T11:38:00","date_gmt":"2023-05-30T11:38:00","guid":{"rendered":"https:\/\/content.technikum-wien.at\/?post_type=news&p=42300"},"modified":"2025-09-08T09:29:47","modified_gmt":"2025-09-08T09:29:47","slug":"fh-technikum-wien-conducts-research-on-artificial-nerve-grafts","status":"publish","type":"news","link":"https:\/\/content.technikum-wien.at\/en\/news\/fh-technikum-wien-conducts-research-on-artificial-nerve-grafts\/","title":{"rendered":"UAS Technikum Wien conducts research on artificial nerve grafts"},"content":{"rendered":"\n
\n
\n

A team of researchers at the FH Technikum Wien is working on promising artificial nerve grafts to treat peripheral nerve injuries. In addition, the developments at the Technikum can help to reduce animal testing.

Peripheral nerve injuries are nerve injuries outside the brain, for example in the nerves of the hand, for example due to an accident. Such damage significantly affects the quality of life of patients and can lead to the loss of motor and sensory functions. Current therapy is based on nerve grafts from the patient’s own body, but this involves loss of function of the donor nerve – sacrificing a healthy nerve to restore the function of the injured nerve.

“There is an urgent need for alternative therapies, such as the production of artificial nerve grafts, which my team has set itself the goal of researching and developing,” says Andreas Teuschl-Woller, head of the research focus Tissue Engineering & Molecular Life Science Technologies at UAS Technikum Wien.<\/p>\n\n\n\n

Innovative approach with patent application<\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/h2>\n\n\n\n

Researcher Carina Hromada is pursuing an approach that takes the natural regeneration processes in the body after nerve injuries as a model. After nerve injuries, so-called glial cells (also called “Schwann cells”) can form longitudinal cell tracks (B\u00fcngner’s ligaments) between the severed nerve endings, which serve as guide structures for regenerating, regrowing axons.

 In detail:  

Carina Hromada is exploring the approach of engineering longitudinally aligned Schwann cells in a biocompatible matrix.
For these artificial B\u00fcngner tapes, Schwann cells are embedded in three-dimensional protein hydrogels, applied to a special hook holder and then mechanically trained using the “MagneTissue” bioreactor developed in-house.
Schwann cells can thus be subjected to tensile stress by interacting a magnet integrated into the hook holder with an external motor-controlled magnet of the bioreactor (Fig. 1A).
This leads to longitudinal alignment along the tensile axis and formation of a specific regenerative phenotype of Schwann cells, as also found in B\u00fcngner tapes.

The innovative idea of aligning Schwann cells with the help of active mechanical stimulation was internationally protected by the research team of the FH Technikum Wien with a patent application.<\/p>\n\n\n\n

New regeneration model<\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/h2>\n\n\n\n

In order to be able to predict the regenerative capacity of artificial nerve grafts in the body, Hromada is also working on establishing a cell-based regeneration model for peripheral nerves, which is intended to mimic the regenerative processes after injuries outside the body.

In detail:

This involves combining Schwann cell constructs with dorsal root ganglia and examining the outgrowth of axons along previously aligned Schwann cells.
It was shown that regenerating axons orient along the artificial B\u00fcngner ligaments, as hoped, and thus successfully innervate the construct (Fig. 1B) – and this could thus represent a promising alternative to autologous grafts in the clinic in the future.

The long-standing collaboration with the Ludwig Boltzmann Institute (LBI) for Traumatology (the research center in cooperation with AUVA), specifically with the neuroregeneration group of David Hercher, allows to bring the research results into a clinical context. This is an essential step to develop such cell-based therapies specifically for their clinical use.<\/p>\n\n\n\n

Further opportunities, among others, in reduction of animal experiments<\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/h2>\n\n\n\n

The above-mentioned nerve-like axon-Schwann cell constructs offer a variety of further possibilities that are currently being tested. Currently, the combination with macrophage models is being worked on within the framework of the City of Vienna project “ImmunTissue” (MA23 30-06), which will serve to further evaluate the constructs. These models also have further relevance for research and clinical application as a possible drug screening platform to detect potentially neurotoxic effects of new and established drugs (which are e.g. used as specific chemotherapeutic agents). This can not only significantly reduce animal testing and associated costs, but also better predict the success of clinical trials.

Pictured:<\/strong> Development of artificial B\u00fcngner tapes. Image A: The “MagneTissue” bioreactor is used to longitudinally align Schwann cells in protein hydrogels using two magnets. Figure B: The artificial B\u00fcngner’s ligaments are tested in a regeneration model with regard to their regenerative capacity. Axons (green) grow as hoped along the longitudinally aligned Schwann cells (red); blue: cell nuclei. Copyright for both images: FH Technikum Vienna.<\/p>\n\n\n\n

Links\/ Scientific Publications<\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/h2>\n\n\n\n